miransertib
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01473095)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Allosteric inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1- Mol. weight
- 432.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297188 ↗
- ChEMBLCHEMBL3545422 ↗
Also known as
- arq 092
- arq 092
- arq-092
- arq-092
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04980872 | Phase 2 | Nov 2, 2021 | Merck |
| NCT04316546 | Phase 2 | Apr 23, 2020 | National Human Genome Research Institute (NHGRI) |
| NCT03094832 | Phase 1/Phase 2 (Phase 2) | May 30, 2017 | ArQule |
| NCT02594215 | Phase 1 | Oct 29, 2015 | National Human Genome Research Institute (NHGRI) |
| NCT02476955 | Phase 1 | Jun 1, 2015 | ArQule |
| NCT01473095 | Phase 1 | Nov 1, 2011 | ArQule |
| NCT03317366 | N/A | — | ArQule |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ArQule | For profit | 4 | 4 | 3 | 2011 |
| National Human Genome Research Institute (NHGRI) | Government | 2 | 2 | 2 | 2015 |
| Merck | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1